Emergent BioSolutions, PharmAthene, U.S. Department of Health and Human Services infectious news

Emergent and PharmAthene will now be required to submit to FDA a comprehensive regulatory strategy for their respective recombinant protective antigen ( rPA) anthrax vaccines, after HHS asked for addi...